Could a lupus drug unlock kidney transplants for Hard-to-Match patients?

NCT ID NCT07539857

Not yet recruiting Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a short course of belimumab, a drug used for lupus, can improve detection of immune cells that cause transplant rejection. The goal is to help highly sensitized kidney transplant candidates—people whose immune systems are very picky about donor organs—get matched faster. Twenty-five adults will receive belimumab and provide blood samples to see if it changes their immune profile and leads to more donor offers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belimumab (Benlysta)
What this could lead to: If successful, this could help highly sensitized kidney transplant candidates get donor organs faster and more safely by improving immune matching.
What could go wrong: This is a small, early-phase study with only 25 participants, so results may not apply broadly. Belimumab may not effectively mobilize the targeted cells, and the approach may not improve transplant access.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT REJECTION

Contacts and locations

Locations

Leiden University Medical Centre

Leiden, 2333 ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.